A Phase 1 Open Label/ Phase 2 Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma.

Trial Profile

A Phase 1 Open Label/ Phase 2 Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 09 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 28 Apr 2012 Additional trial location (Germany) identified as reported by EudraCT.
    • 31 Oct 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top